文献速递泌尿生殖腹部PETCT

延迟18F FDG PET/CT显像在膀胱癌经尿道切除术后残留肿瘤评估中的应用

Delayed 18F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer.
PubMed 文献 · Radiology · 2019-08-13

回顾性研究纳入2015年1月至2018年4月间79例膀胱癌患者,在初次经尿道膀胱肿瘤电切术(TURBT)后1个月内行18F FDG PET/CT,共分析98个病灶,其中64个(65.3%)为残留肿瘤。残留肿瘤的SUVmean(9.3±5.4 vs 5.8±2.0,P<.001)、SUVmax(22.2±13.6 vs 15.5±9.8,P=.01)及病灶厚度(17.9 mm±11.1 vs 9.6 mm±4.1,P<.001)均高于炎症反应;SUVmean(OR 1.2,95%CI 1.0–1.5,P=.049)与病灶厚度(OR 1.2,95%CI 1.0–1.3,P=.006;或OR 1.2,95%CI 1.1–1.3,P=.001)为残留肿瘤的独立预测因素。

要点

  • TURBT术后1个月内延迟18F FDG PET/CT可用于鉴别残留肿瘤与术后炎症反应。
  • 残留肿瘤的SUVmean、SUVmax及病灶厚度均高于炎症反应,差异有统计学意义。
  • SUVmean与病灶厚度是残留肿瘤的独立预测因素,低、中、高风险亚组预测率分别为37.5%、85.4%、98.3%。

核心结论

  • 延迟18F FDG PET/CT鉴别TURBT术后病灶时,较高的平均标准化摄取值和较大的病灶厚度是膀胱癌患者肿瘤治疗后残留肿瘤的预测因素。

研究设计与样本

  • 回顾性临床研究,纳入2015年1月至2018年4月间79例膀胱癌患者(61男、18女,平均年龄63岁±11),均在初次TURBT后1个月内行18F FDG PET/CT,随后2周内行第二次手术以病理确认可疑病灶性质并切除残留肿瘤;采用单因素和多因素分析筛选残留膀胱肿瘤的预测因素。

诊断标准与关键数值

  • 残留肿瘤与炎症反应比较:SUVmean 9.3±5.4 vs 5.8±2.0(P<.001),SUVmax 22.2±13.6 vs 15.5±9.8(P=.01),病灶厚度17.9 mm±11.1 vs 9.6 mm±4.1(P<.001);多因素logistic回归中SUVmean(OR 1.2,95%CI 1.0–1.5,P=.049)和病灶厚度(OR 1.2,95%CI 1.0–1.3,P=.006;或OR 1.2,95%CI 1.1–1.3,P=.001)为独立预测因素;基于SUVmean和病灶厚度阈值,低、中、高风险亚组残留肿瘤预测率分别为37.5%(17/47)、85.4%(26/29)、98.3%(21/22)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Delayed fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT is used to diagnose bladder cancer. However, it remains difficult to determine whether a lesion with abnormal 18F FDG uptake is tumor residue or recurrence or if it is an inflammatory reaction in patients with bladder cancer after oncologic treatment. Purpose To determine the diagnostic performance of delayed 18F FDG PET/CT in the differentiation of residual tumors from postoperative inflammatory reactions in patients with bladder cancer after initial transurethral resection of bladder tumor (TURBT). Materials and Methods A retrospective clinical study between January 2015 and April 2018 was performed in 79 patients with bladder cancer who had undergone 18F FDG PET/CT within 1 month after initial TURBT. After PET/CT, all patients underwent a second surgery within 2 weeks to confirm the histologic nature of the suspicious lesion and to remove residual tumors. Uni- and multivariable analysis were used to identify predictive factors for residual bladder tumors. Results A total of 79 patients (61 men, 18 women; mean age, 63 years ± 11 [standard deviation]) were enrolled in this study. A total of 98 lesions was studied, 64 (65.3%) of which were residual tumors after initial TURBT. When compared with inflammatory reactions, residual tumors had higher mean standardized uptake value (SUVmean) (mean, 5.8 ± 2.0 vs 9.3 ± 5.4; P < .001), higher maximum standardized uptake value (SUVmax) (mean, 15.5 ± 9.8 vs 22.2 ± 13.6, P = .01), and greater lesion thickness (mean, 9.6 mm ± 4.1 vs 17.9 mm ± 11.1, P < .001) at 18F FDG PET/CT. SUVmean (odds ratio [OR], 1.2; 95% confidence interval [CI]: 1.0, 1.5; P = .049) and lesion thickness (OR, 1.2; 95% CI: 1.0, 1.3; P = .006 or OR, 1.2; 95% CI: 1.1, 1.3; P = .001) were identified as independent predictors for residual tumors with multivariable logistic regression analysis. On the basis of the threshold values of SUVmean and lesion thickness, we revealed a prediction rate of 37.5% (17 of 47), 85.4% (26 of 29), and 98.3% (21 of 22) for residual tumors in low-, moderate-, and high-risk subgroups, respectively. Conclusion Use of fluorine 18 fluorodeoxyglucose PET/CT to differentiate lesions after transurethral resection of bladder tumor indicates that higher mean standardized uptake values and greater lesion thickness are predictive factors for residual tumors in patients with bladder cancer after oncologic treatment. Published under a CC BY 4.0 license.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Yan H, Zhou X, Wang X, et al. Delayed 18F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer. Radiology. 2019. PMID: 31407969. doi:10.1148/radiol.2019190032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。